High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents.
S StänderN BhatiaMelinda J GooderhamJonathan Ian SilverbergJacob Pontoppidan ThyssenP BiswasM DiBonaventuraW RomeroS A FarooquiPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
NCT02780167, NCT03349060 and NCT03575871.